Udvalget fandt, at fordelene ved Busilvex opvejer risiciene som konditionerende behandling før transplantation af bloddannende progenitorceller.
The Committee decided that Busilvex’ s benefits are greater than its risks as conditioning treatment prior to haematopoietic progenitor cell transplantation.